KR930003906A - 약학적 구상 제형 - Google Patents

약학적 구상 제형 Download PDF

Info

Publication number
KR930003906A
KR930003906A KR1019920013984A KR920013984A KR930003906A KR 930003906 A KR930003906 A KR 930003906A KR 1019920013984 A KR1019920013984 A KR 1019920013984A KR 920013984 A KR920013984 A KR 920013984A KR 930003906 A KR930003906 A KR 930003906A
Authority
KR
South Korea
Prior art keywords
composition
release
diltiazem
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
KR1019920013984A
Other languages
English (en)
Other versions
KR100221695B1 (ko
Inventor
리챠드 벅스톤 이안
크리츨리 헬렌
토마스 레슬리에 스트워트
떼레세 안토이네트 말코우스카 산드라
알란 프라터 데렉
브라운 밀러 로널드
Original Assignee
원본미기재
유로셀티크 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919117361A external-priority patent/GB9117361D0/en
Priority claimed from GB919122967A external-priority patent/GB9122967D0/en
Application filed by 원본미기재, 유로셀티크 에스.에이. filed Critical 원본미기재
Publication of KR930003906A publication Critical patent/KR930003906A/ko
Application granted granted Critical
Publication of KR100221695B1 publication Critical patent/KR100221695B1/ko

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/501Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5015Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fertilizers (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

내용 없음.

Description

약학적 구상 제형
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (12)

  1. 딜티아젬이나 약학적으로 허용가능한 이의 염과 임의의 구상화제로 이루어지고, 방출 조절물질로 코팅된 구상코아를 포함하는 방출조절 조성물.
  2. 제1항에 있어서, 구상코아는 40중량%-98% 사이의 딜티아젬이나 약학적으로 허용가능한 이의 염을 포함함을 특징으로 하는 조성물.
  3. 제2항에 있어서. 구상코아는 70중량%-85중량% 사이의 딜티아젬이나 약학적으로 허용가능한 이의 염을 포함함을 특징으로 하는 조성물.
  4. 제1-3항 중의 어느 한 항에 있어서, 구상화제는 구상코아의 15중량%-40중량%의 양으로 존재함을 특징으로 하는 조성물.
  5. 제4항에 있어서, 구상화제는 마이크로크리스탈린 셀룰로오스를 포함함을 특징으로 하는 조성물.
  6. 제1-5항 중의 어느 한 항에 있어서, 방출조절 코팅물질은 수불용성 폴리머를 포함함을 특징으로 하는 조성물.
  7. 제6항에 있어서, 코팅물질은 에틸셀룰로오스를 포함함을 특징으로 하는 조성물.
  8. 제1-7항 중의 어느 한 항에 있어서, 방출조절 코팅물질은 하나 또는 그 이상의 가소제, 계면활성제와 택-개량제를 포함함을 특징으로 하는 조성물.
  9. 제8항에 있어서, 방출조절 코팅제는 50%-95%의 에틸셀룰로오스, 5%-15%의 콜로이드성 무수 실리카, 5%-15%의 디부틸 세바케이트와 5%-15%의 폴리솔베이트 80을 포함함을 특징으로 하는 조성물.
  10. 제1-9항 중의 어느 한 항에 있어서, 방출조절 코팅물질은 조성물의 2중량%-8중량%의 양으로 존재함을 특징으로 하는 조성물.
  11. 제1-10항 중의 어느 한 항에 따르는 방출조절 코팅된 구상코아를 포함하는 캡슐제.
  12. (a)-(e)를 포함하는 제1-10항 중의 어느 한 항에 따르는 조성물의 제조방법.
    (a) 딜티아젬이나 약학적으로 허용가능한 이의 염, 물과 임의의 구상화제를 포함하는 혼합물을 과립화시키고; (b) 압출물을 만들기 위해 과립화된 혼합물을 압출시키며; (d) 구상코아를 건조시키며; (e) 방출조절 물질로 구상코아를 코팅시킨다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920013984A 1991-08-12 1992-08-04 약학적 구상 제형 KR100221695B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB919117361A GB9117361D0 (en) 1991-08-12 1991-08-12 Oral dosage form
GB9117361.7 1991-08-12
GB9122967.4 1991-10-29
GB919122967A GB9122967D0 (en) 1991-10-29 1991-10-29 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
KR930003906A true KR930003906A (ko) 1993-03-22
KR100221695B1 KR100221695B1 (ko) 1999-09-15

Family

ID=26299395

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920013984A KR100221695B1 (ko) 1991-08-12 1992-08-04 약학적 구상 제형

Country Status (14)

Country Link
US (2) US5670172A (ko)
EP (1) EP0527637B1 (ko)
JP (1) JP3019235B2 (ko)
KR (1) KR100221695B1 (ko)
CN (1) CN1052398C (ko)
AT (1) ATE165513T1 (ko)
AU (1) AU651715B2 (ko)
CA (1) CA2075356A1 (ko)
DE (1) DE69225278D1 (ko)
ES (1) ES2115643T3 (ko)
FI (1) FI923582A (ko)
IL (1) IL102778A (ko)
NO (1) NO304406B1 (ko)
PH (1) PH31288A (ko)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
FR2702160B1 (fr) * 1993-03-02 1995-06-02 Biovecteurs As Vecteurs particulaires synthétiques et procédé de préparation.
SE9301220D0 (sv) * 1993-04-14 1993-04-14 Kabi Pharmacia Ab Manufacturing matrices
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5834024A (en) * 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
US5914134A (en) * 1997-01-27 1999-06-22 Wockhardt Europe Limited Process for the pulsatile delivery of diltiazem HCL and product produced thereby
US7060734B1 (en) 1997-09-09 2006-06-13 Alza Corporation Pharmaceutical coating composition and method of use
JP2001515855A (ja) * 1997-09-09 2001-09-25 アルザ・コーポレーション 薬剤コーティング組成物と使用方法
US5891845A (en) * 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
EP1041988A4 (en) * 1997-12-22 2002-03-13 Euro Celtique Sa METHOD FOR PREVENTING ABUSE OF OPIOID DOSES FORMS
RS50070B (sr) 1997-12-22 2009-01-22 Euro-Celtique S.A., Oralni dozni oblik sa kombinacijom opijatnog agonista i antagonista
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
US6432448B1 (en) 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
US6723342B1 (en) 1999-02-08 2004-04-20 Fmc Corporation Edible coating composition
US6410255B1 (en) * 1999-05-05 2002-06-25 Aurora Biosciences Corporation Optical probes and assays
NZ515675A (en) 1999-05-14 2004-06-25 Nereus Pharmaceuticals Inc Novel interleukin-1 and tumor necrosis factor-alpha modulators, syntheses of said modulators and methods of using said modulators
GB9913979D0 (en) 1999-06-17 1999-08-18 Univ Wales Medicine Spheroid preparation
ATE526950T1 (de) * 1999-10-29 2011-10-15 Euro Celtique Sa Hydrocodon-formulierungen mit gesteuerter freisetzung
US6500462B1 (en) 1999-10-29 2002-12-31 Fmc Corporation Edible MCC/PGA coating composition
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
US7108866B1 (en) 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
US20060153914A1 (en) * 1999-12-10 2006-07-13 Biovail Laboratories International S.R.L. Chronotherapeutic diltiazem formulations and the administration thereof
EP2517710B1 (en) 2000-02-08 2015-03-25 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
CA2400642A1 (en) * 2000-02-23 2001-08-30 Vertex Pharmaceuticals (San Diego) Llc Modified fluorescent proteins
US6852031B1 (en) * 2000-11-22 2005-02-08 Igt EZ pay smart card and tickets system
US6635277B2 (en) 2000-04-12 2003-10-21 Wockhardt Limited Composition for pulsatile delivery of diltiazem and process of manufacture
GB0025208D0 (en) * 2000-10-13 2000-11-29 Euro Celtique Sa Delayed release pharmaceutical formulations
EP2263658A1 (en) 2000-10-30 2010-12-22 Euro-Celtique S.A. Controlled release hydrocodone formulations
AU4322802A (en) * 2000-11-16 2002-06-24 Univ California Marine actinomycete taxon for drug and fermentation product dicovery
TR200300731T2 (tr) 2000-11-28 2004-08-23 Fmc Corporation Yenebilir PGA kaplama bileşimi
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
ATE419039T1 (de) 2001-07-18 2009-01-15 Euro Celtique Sa Pharmazeutische kombinationen von oxycodon und naloxon
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030157168A1 (en) * 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
DE60232417D1 (de) 2001-08-06 2009-07-02 Euro Celtique Sa Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
DK2425824T5 (en) 2002-04-05 2018-02-12 Mundipharma As Pharmaceutical preparation containing oxycodone and naloxone
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
EP2422772A3 (en) 2002-09-20 2012-04-18 Alpharma, Inc. Sequestering subunit and related compositions and methods
AU2003296908A1 (en) * 2002-09-27 2004-05-04 Nereus Pharmaceuticals, Inc. Macrocyclic lactams
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
US20040208932A1 (en) * 2003-04-17 2004-10-21 Ramachandran Thembalath Stabilized paroxetine hydrochloride formulation
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
NZ544588A (en) * 2003-06-20 2010-06-25 Nereus Pharmaceuticals Inc Use of salinosporamide A and analogs thereof for the treatment of cancer, inflammation and infectious diseases
ZA200600473B (en) * 2003-06-20 2007-04-25 Univ California Salinosporamides and methods for use thereof
CA2445420A1 (en) * 2003-07-29 2005-01-29 Invitrogen Corporation Kinase and phosphatase assays
US7727752B2 (en) * 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
US7619059B2 (en) * 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
CA2538797A1 (en) * 2003-09-12 2005-03-24 Invitrogen Corporation Multiplex binding and activity assays
EP1711486B1 (en) * 2004-01-23 2011-05-11 Nereus Pharmaceuticals, Inc. Bis-indole pyrroles useful as antimicrobial agents
EP1812443A2 (en) 2004-04-30 2007-08-01 Nereus Pharmaceuticals, Inc. [3.2.0] heterocyclic compounds and methods of using the same
US7579371B2 (en) 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
WO2006058059A2 (en) 2004-11-23 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition comprising a sustained release coating or matrix and an nmda receptor antagonist, method for administration such nmda antagonist to a subject
EP1845968A2 (en) 2004-11-24 2007-10-24 Neuromolecular Pharmaceuticals, Inc Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
US20070225350A1 (en) * 2004-12-03 2007-09-27 Anderson Kenneth C Compositions and methods for treating neoplastic diseases
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
AU2006228535A1 (en) * 2005-03-31 2006-10-05 Rafael Armament Development Authority Ltd. Apparatus for treating particles and liquids by ultrasound
MX2007012374A (es) 2005-04-06 2008-02-22 Adamas Pharmaceuticals Inc Metodos y composiciones para el tratamiento de condiciones relacionadas con cns.
WO2007015757A2 (en) 2005-07-21 2007-02-08 Nereus Pharmaceuticals, Inc. Interleukin-1 and tumor necrosis factor-a modulators; syntheses of such modulators and methods of using such modulators
KR101486228B1 (ko) 2006-06-19 2015-01-26 알파마 파머슈티컬스 엘엘씨 약제학적 조성물
CA2671200A1 (en) * 2006-07-21 2008-01-24 Lab International Srl Hydrophilic abuse deterrent delivery system
EP1920767A1 (en) * 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form
WO2008095195A2 (en) * 2007-02-02 2008-08-07 Nereus Pharmaceuticals, Inc. Lyophilized formulations of salinosporamide a
US20090017167A1 (en) * 2007-07-11 2009-01-15 Herbalife International Inc. Mixture and beverage made therefrom for protecting cellular hydration
US8394816B2 (en) * 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
WO2009088673A2 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
EP2219612A4 (en) * 2007-12-17 2013-10-30 Paladin Labs Inc CONTROLLED RELEASE FORMULATION AVOIDING IMPROPER USES
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
MX2010012341A (es) * 2008-05-12 2010-12-06 Nereus Pharmaceuticals Inc Derivados de salinosporamida como inhibidores de proteasoma.
CN105456267A (zh) * 2008-07-07 2016-04-06 欧洲凯尔特公司 阿片类拮抗剂治疗尿潴留的用途
WO2010103039A1 (en) 2009-03-10 2010-09-16 Euro-Celtique S.A. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
CA2782556C (en) 2009-12-02 2018-03-27 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
US10463611B2 (en) 2011-06-08 2019-11-05 Sti Pharma, Llc Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
ITFI20110172A1 (it) * 2011-08-08 2013-02-09 Valpharma Sa Formulazione multiparticolata a rilascio modificato di diltiazem hcl.
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
AU2014295042B2 (en) 2013-07-23 2017-03-30 Mundipharma Pty Limited A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
MX2017002750A (es) 2014-09-02 2017-08-02 Singh Bhupinder Metodo para marcar una molecula deuterada o no deuterada y formulaciones farmaceuticas para tratamiento.
IL251588B2 (en) 2014-10-08 2024-09-01 Pacific Northwest Res Institute Methods and preparations for increasing the potency of antifungal agents
EP3397253A1 (en) 2015-12-30 2018-11-07 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders
WO2018200885A1 (en) 2017-04-26 2018-11-01 Neurocentria, Inc. Magnesium compositions and methods of use
CN112533614A (zh) 2018-03-28 2021-03-19 美国康宝莱国际公司 多糖的乙酰化

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456628A (en) * 1981-01-07 1984-06-26 Bauer Kurt H Process for film-coating a particulate solid, and emulsions for conducting the process
DK152744C (da) * 1982-08-13 1988-10-31 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat
US4898729A (en) * 1983-12-09 1990-02-06 Euroceltique, S.A. Treatment of hypertension, compounds and compositions for antihypertension and diuresis
US4917899A (en) * 1983-12-22 1990-04-17 Elan Corporation Plc Controlled absorption diltiazem formulation
US5364620A (en) * 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4894240A (en) * 1983-12-22 1990-01-16 Elan Corporation Plc Controlled absorption diltiazem formulation for once-daily administration
US5002776A (en) * 1983-12-22 1991-03-26 Elan Corporation, Plc Controlled absorption diltiazem formulations
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
DE3403329A1 (de) * 1984-02-01 1985-08-01 Horst Dr. 4019 Monheim Zerbe Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe
US4643731A (en) * 1985-08-16 1987-02-17 Alza Corporation Means for providing instant agent from agent dispensing system
JPS62103012A (ja) * 1985-10-23 1987-05-13 Eisai Co Ltd 多重顆粒
IT1200217B (it) * 1986-09-30 1989-01-05 Valducci Roberto Membrana per uso farmaceutico ed industriale
DE3709188A1 (de) * 1987-03-20 1988-09-29 Mannesmann Ag Ausgiessrohr fuer metallurgische gefaesse
GB8707421D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
CA1323833C (en) * 1987-04-28 1993-11-02 Yatindra M. Joshi Pharmaceutical compositions in the form of beadlets and method
US4808413A (en) * 1987-04-28 1989-02-28 E. R. Squibb & Sons, Inc. Pharmaceutical compositions in the form of beadlets and method
BE1000794A4 (nl) * 1987-07-30 1989-04-04 Schelde Delta Bv Met Beperkte Werkwijze voor het bij chemische processen immobiliseren van komponenten in een fluidumstroom, en inrichtingen die deze werkwijze toepassen.
US4814181A (en) * 1987-09-03 1989-03-21 Alza Corporation Dosage form comprising fast agent delivery followed by slow agent delivery
US5219621A (en) * 1987-10-16 1993-06-15 Elan Corporation, Plc Methods of treatment with diltiazem formulations
AU615221B2 (en) * 1987-10-16 1991-09-26 Elan Corporation, Plc Controlled absorption diltiazem formulations
IL88083A (en) * 1987-11-06 1992-11-15 Tanabe Seiyaku Co Controlled release pharmaceutical dosage form and its preparation
DE3739779A1 (de) * 1987-11-24 1989-06-08 Beiersdorf Ag Pharmazeutische praeparate
FR2623714B1 (fr) * 1987-11-26 1990-04-20 Ethypharm Sa Forme a liberation prolongee du diltiazem, et son medicament ainsi obtenu
FR2624732B1 (fr) * 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
JP2643222B2 (ja) * 1988-02-03 1997-08-20 エーザイ株式会社 多重層顆粒
GB8805695D0 (en) * 1988-03-10 1988-04-07 Nycomed As Enteric coated spheroidal granules
FI101344B (fi) * 1988-03-31 1998-06-15 Tanabe Seiyaku Co Menetelmä valmistaa valmiste, josta kontrolloidusti vapautuu farmaseut tisesti aktiivista ainetta
FR2630647B1 (fr) * 1988-04-27 1991-08-16 Sanofi Sa Microbilles de diltiazem, leur procede de fabrication et compositions pharmaceutiques a liberation prolongee les contenant
ZA899071B (en) * 1988-11-30 1990-08-29 Schering Corp Sustained release diltiazem formulation
SE506179C2 (sv) * 1989-01-23 1997-11-17 Ciba Geigy Ag Farmaceutisk lågkomposition av benazepril och ett tiaziddiuretikum
SE8902699D0 (sv) * 1989-08-09 1989-08-09 Lejus Medical Ab Diltiazem containing pharmaceutical compositios
JPH0674206B2 (ja) * 1989-12-28 1994-09-21 田辺製薬株式会社 放出制御型製剤およびその製法
IT1241417B (it) * 1990-03-06 1994-01-14 Vectorpharma Int Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione
ZA923474B (en) * 1991-05-20 1993-01-27 Marion Merrell Dow Inc Diltiazem formulation
US5286497A (en) * 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation

Also Published As

Publication number Publication date
CA2075356A1 (en) 1993-02-13
FI923582A0 (fi) 1992-08-11
JPH05201867A (ja) 1993-08-10
CN1069408A (zh) 1993-03-03
JP3019235B2 (ja) 2000-03-13
NO304406B1 (no) 1998-12-14
US5670172A (en) 1997-09-23
ATE165513T1 (de) 1998-05-15
AU2088092A (en) 1993-02-18
ES2115643T3 (es) 1998-07-01
EP0527637B1 (en) 1998-04-29
IL102778A (en) 1999-05-09
NO923128D0 (no) 1992-08-11
US5601845A (en) 1997-02-11
NO923128L (no) 1993-02-15
FI923582A (fi) 1993-02-13
IL102778A0 (en) 1993-01-31
DE69225278D1 (de) 1998-06-04
EP0527637A1 (en) 1993-02-17
CN1052398C (zh) 2000-05-17
AU651715B2 (en) 1994-07-28
KR100221695B1 (ko) 1999-09-15
PH31288A (en) 1998-07-06

Similar Documents

Publication Publication Date Title
KR930003906A (ko) 약학적 구상 제형
KR930003905A (ko) 약학적 결합 제제
DE69807104D1 (de) Formulierungen mit gesteuerter freisetzung
KR870700344A (ko) 유효 화합물을 서서히 방출하는 신규 약제, 그의 제조방법 및 이신규 제제물의 용도
DK0868912T3 (da) Anvendelse af redispergerbare polymerpulvere eller polymergranulater til coating af farmaceutiske eller agrokemiske applikationsformer
NO178136C (no) Framgangsmåte for framstilling av et preparat for styrt frigjöring av en farmasöytisk aktiv substans
DE3865077D1 (de) Ibuprofenmatrix mit verzoegerter freisetzung und verfahren.
BR9806174A (pt) Péletes tendo um núcleo revestido com um antifúngico e um polìmero
FI906344A0 (fi) Kontrollerat frigoerande farmaceutiskt preparat.
KR920002135A (ko) 대장에서만 방출할수 있는 피복시킨 고체 약물형태
KR860006984A (ko) 서방성 제제의 제조방법
ES2175073T3 (es) Procedimiento de preparacion de formas para la administracion oral de antibioticos beta-lactamicos de rapida dispersabilidad en agua.
KR970703774A (ko) 활성물질 방출이 지연된 카바마제핀 약제(Carbamazepine medicament with retarded active substance release)
JPH0459723A (ja) 口腔内貼着型膜製剤
MX9203020A (es) Microesferas de diltiazem y composiciones farmaceuticas de liberacion prolongada que las contienen.
JPS54126722A (en) Slow release antibiotic tablet
ATE112158T1 (de) Pharmazeutische zusammensetzungen mit unterschiedlicher wirkstoffabgabe.
JPS648979A (en) Gap release agent for forming balloon part of catheter
KR970032869A (ko) 딜티아젬의 서방형 펠렛 제형

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120625

Year of fee payment: 14

EXPY Expiration of term